Safety is a top priority for CHMP. The committee employs a multi-faceted approach to ensure drug safety:
Rigorous Clinical Trials: Only drugs that have undergone extensive clinical testing are considered. Adverse Event Monitoring: Post-marketing surveillance is conducted to monitor any adverse events. Risk-Benefit Analysis: A comprehensive risk-benefit analysis is performed to determine whether the benefits of the drug outweigh the risks.
